NeuroBo Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Corporate Update
| NRBODelisted Stock | USD 1.76 0.38 17.76% |
About 61% of Neurobo Pharmaceuticals' investor base is looking to short. The analysis of current outlook of investing in Neurobo Pharmaceuticals suggests that many traders are alarmed regarding Neurobo Pharmaceuticals' prospects. Neurobo Pharmaceuticals' investing sentiment overview a quick insight into current market opportunities from investing in Neurobo Pharmaceuticals. Many technical investors use Neurobo Pharmaceuticals stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Neurobo |
NeuroBo Pharmaceuticals, Inc. , a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced financial results for the third quarter ended September 30, 2024 and provided a corporate update.
Read at finance.yahoo.com
 |
Neurobo Pharmaceuticals Fundamental Analysis
We analyze Neurobo Pharmaceuticals' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Neurobo Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Neurobo Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Total Debt
Total Debt Comparative Analysis
Neurobo Pharmaceuticals is currently under evaluation in total debt category among its peers. Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Neurobo Pharmaceuticals Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Neurobo Pharmaceuticals stock to make a market-neutral strategy. Peer analysis of Neurobo Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Neurobo Pharmaceuticals by comparing valuation metrics with similar companies.
Peers
Neurobo Pharmaceuticals Related Equities
| CDIO | Cardio Diagnostics | 10.34 | ||||
| BDRX | Biodexa Pharmaceticals | 10.02 | ||||
| VRAX | Virax Biolabs | 9.95 | ||||
| ZURA | Zura Bio | 9.79 | ||||
| SONN | Sonnet Biotherapeutics | 9.37 | ||||
| QNRX | Quoin Pharmaceuticals | 4.48 | ||||
| PHIO | Phio Pharmaceuticals | 3.68 | ||||
| KPRX | Kiora Pharmaceuticals | 1.40 | ||||
| REVB | Revelation Biosciences | 1.52 | ||||
| ALLR | Allarity Therapeutics | 4.50 | ||||
| ATNF | 180 Life | 5.49 |
Check out Neurobo Pharmaceuticals Hype Analysis, Neurobo Pharmaceuticals Correlation and Neurobo Pharmaceuticals Performance. You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Other Consideration for investing in Neurobo Stock
If you are still planning to invest in Neurobo Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Neurobo Pharmaceuticals' history and understand the potential risks before investing.
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals |